Straits Times Index
3,327.88 +9.43 (+0.28%) Nikkei
38,775.14 -124.88 (-0.32%) Hang Seng
18,977.88 +150.53 (+0.80%) FTSE 100
8,317.59 -21.64 (-0.26%) Bitcoin USD
68,622.73 -579.65 (-0.84%) CMC Crypto 200
1,490.42 +6.23 (+0.42%)
BNTX Dec 2024 125.000 call
| Previous close | 4.8000 |
| Open | 2.8000 |
| Bid | 2.1500 |
| Ask | 3.9000 |
| Strike | 125.00 |
| Expiry date | 2024-12-20 |
| Day's range | 2.8000 - 4.8000 |
| Contract range | N/A |
| Volume | |
| Open interest | 107 |
PR NewswireMediLink Therapeutics announces a multi-target TMALIN® ADC technology platform license agreement with BioNTech, expanding their global strategic partnership
MediLink Therapeutics (Suzhou) Co., Ltd. ("MediLink"), a clinical-stage biotech company, today announces a new strategic collaboration with BioNTech SE (Nasdaq: BNTX, "BioNTech"), a next-generation immunotherapy company pioneering novel therapies for cancer and other serious diseases, under which BioNTech will receive an exclusive option to an exclusive global license to apply MediLink's TMALIN® antibody-drug conjugate (ADC) platform, for several novel targets chosen by BioNTech.
GlobeNewswireBioNTech to Present Clinical Data Updates for Next-Generation Immunotherapy Candidates at the ASCO Annual Meeting 2024
MAINZ, Germany, May 21, 2024 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present clinical trial data for selected programs from the Company’s diversified immuno-oncology pipeline at the American Society of Clinical Oncology (“ASCO”) Annual Meeting in Chicago, Illinois, from May 31 to June 4, 2024. Moreover, in support of the Company’s ongoing CAR-T cell and individualized mRNA programs, BioNTech will also present epidemiological and real-world data from two observational studi
- Thomson Reuters StreetEvents
Q1 2024 Autolus Therapeutics PLC Earnings Call
Q1 2024 Autolus Therapeutics PLC Earnings Call
